TEVA

Teva Pharmaceutical Industries Limited (TEVA) ESG Analysis Analysis (2026)

Invetso Score: 6.3/10 — Balanced · Last Updated: 2026-10-01

Environmental

TEVA’s R&D intensity near 9.8% of revenue supports process and formulation innovation, but peers in specialty pharma often sustain higher science-led investment.

The company’s manufacturing footprint likely creates energy, water, and waste exposure typical of generics producers, leaving it broadly in line with peers rather than advantaged.

No post-August 2025 disclosure was provided on emissions, renewable energy, or waste targets, limiting evidence of a peer-leading environmental transition.

Environmental risk is moderated by the sector’s generally lower direct carbon intensity than heavy industry, yet TEVA still faces comparable compliance and supply-chain scrutiny.

Social

TEVA’s generics and essential medicines portfolio supports broad patient access, a social strength that is common in the sector but not clearly differentiated versus peers.

The company’s R&D spend indicates continued investment in product quality and lifecycle management, which can reduce patient and regulatory risk relative to weaker peers.

No recent disclosure was provided on product recalls, access programs, or workforce safety metrics, preventing confirmation of stronger social performance than peers.

As a large pharmaceutical manufacturer, TEVA remains exposed to quality-control and supply continuity expectations that are material across the peer group.

Governance

TEVA’s leverage is elevated, with debt-to-equity of 2.16x and net debt-to-EBITDA of 4.26x, which can constrain governance flexibility versus less levered peers.

Stock-based compensation at 0.7% of revenue suggests relatively restrained dilution, a modest positive compared with more aggressive peer compensation structures.

The absence of provided filing evidence on board independence, executive accountability, or compliance outcomes limits confidence that governance is stronger than peers.

Given the company’s history as a large global pharma operator, governance quality is likely shaped by litigation, compliance, and capital-allocation oversight more than by ESG leadership.

Overall Score

TEVA’s ESG positioning is broadly average versus peers, with social and environmental characteristics offset by leverage-linked governance constraints.

Score Driver: Elevated Leverage And Limited Disclosed Governance Evidence Versus Peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Teva Pharmaceutical Industries Limited. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →